Since Gli1 is the important tumor‐promoting transcriptional factor and therapeutic target, we utilized the Gli‐dependent luciferase reporter system for evaluating effects of TAMs‐released CCL22 on the intratumoral Gli1 activity and its nuclear location. Here, GLI1 is linked to neoplasm.